Liver disease is a global issue, the prevalence of which is staggering. It is estimated that more than 800 million people worldwide suffer from chronic liver disease and this figure is likely to grow given the ubiquity of alcohol use and obesity.
End-stage liver disease – decompensated cirrhosis – carries with it a high human and healthcare cost.
CyberLiver™ is developing Prescription Digital Therapeutics aimed at halting or reversing the progression of the disease towards this stage, as well as providing effective means of managing the very ill cohort of patients already at this stage.
Decompensated cirrhosis has a high morbidity and mortality rate and necessitates frequent visits to the emergency department, with regular hospitalisation. However, studies show that up to 50% of these re-admissions are preventable. Essentially, continual management is required to prevent complications from becoming acute. We are addressing this critical unmet need.
Learn More
Alcohol consumption is a major cause of chronic liver disease and is on the rise in several regions. We have developed a Digital Therapeutic solution to help in the reduction or cessation or alcohol use in patients with later stages of Alcohol-Related Liver Disease (ARLD)
Learn MoreAlong with alcohol and viruses, obesity is the other main reason people develop chronic liver disease. The incidence of Non-alcoholic Fatty Liver Disease (NAFLD) is increasing rapidly, especially in the West, but there is no effective means of treating those in the more advanced stages. We are developing DTx solutions aimed at helping this population.
Learn More
Software-driven interventions to monitor, treat or manage a medical conditions
Subject to rigorous demonstration of safety and efficacy in Randomised Controlled Trials
Regulated by the US FDA and equivalent bodies elsewhere
Available only via prescription from authorised clinicians
Used either standalone or in conjunction with existing therapies
© 2012-2024 CyberLiver® Ltd. All rights reserved.